Akari Therapeutics Files Two U.S. Provisional Patents For PH1 Payload And Combination ADC Therapy Targeting Immune Activation And Checkpoint Synergy

Author: Benzinga Newsdesk | October 09, 2025 08:48am

Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent applications with the United States Patent and Trademark Office (USPTO). The first application includes claims protecting Akari's novel immuno-oncology payload, PH1 (a novel Thailanstatin analog), and its spliceosome modulatory mechanism of action, which is expected to provide a therapeutic benefit by activating the host immune system in the fight against cancer. The second patent filing includes claims for a combination therapy of PH1 pipeline ADCs with other immuno-oncology drugs that alleviate checkpoint inhibition and have demonstrated synergy with immune checkpoint inhibitors (ICIs) in preclinical models. These new patent applications are part of a growing patent portfolio strategy designed to further extend Akari's proprietary position with respect to the Company's novel PH1 payload. These filings also build upon Akari's recent provisional patent filing in late September covering the use of Akari's ADC platform to target cancer by modulating alternative splicing drivers within cancer cells.

Posted In: AKTX